Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486758 | 0.95 | ALDH1A1 (0.70) | ALDH1A1ACECA12CA7CA9 | |
| SCHEMBL17417900 | 0.85 | ALDH1A1 (0.70) | ALDH1A1ACEGPR34CPA1MME | |
| SCHEMBL28337813 | 0.85 | ALDH1A1 (0.50) | ALDH1A1ACEMAPK1CPA1HTT | |
| SCHEMBL1760821 | 0.85 | ALDH1A1 (0.50) | ALDH1A1ACEMAPK1HTTFOLH1 | |
| SCHEMBL838699 | 0.85 | ALDH1A1 (0.57) | ALDH1A1ACECA2CA12CA7 | |
| SCHEMBL28337815 | 0.85 | ALDH1A1 (0.50) | ALDH1A1ACEMAPK1CPA1HTT | |
| SCHEMBL30062839 | 0.85 | ALDH1A1 (0.57) | ALDH1A1ACECA2CA12CA7 | |
| SCHEMBL29597658 | 0.85 | ALDH1A1 (0.50) | ALDH1A1ACEMAPK1HTTFOLH1 | |
| SCHEMBL1760830 | 0.85 | ALDH1A1 (0.50) | ALDH1A1ACEMAPK1HTTFOLH1 | |
| SCHEMBL148423 | 0.84 | FOLH1 (0.55) | ALDH1A1ACECA2CPA1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341058-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | ADITECH PHARMA AB (SE) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | ALDH1A1 3811/4885ACE 1339/4885CA2 4215/4885 |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | FAH, SLC16A1, FH | ALDH1A1 320/4885ACE 1090/4885CA2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.